Patent: 10,370,449
✉ Email this page to a colleague
Summary for Patent: 10,370,449
Title: | Methods for treating skin infection by administering an IL-4R antagonist |
Abstract: | The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody. |
Inventor(s): | Graham; Neil (Croton-on-Hudson, NY), Ardeleanu; Marius (White Plains, NY), Radin; Allen (New York, NY), Hamilton; Jennifer D. (Hopewell Junction, NY), Teper; Ariel (Hastings-on-Hudson, NY) |
Assignee: | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR) |
Application Number: | 14/632,988 |
Patent Claims: | see list of patent claims |
Details for Patent 10,370,449
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 03/28/2017 | ⤷ Try a Trial | 2034-09-24 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/19/2018 | ⤷ Try a Trial | 2034-09-24 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/18/2020 | ⤷ Try a Trial | 2034-09-24 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 06/14/2021 | ⤷ Try a Trial | 2034-09-24 |
Regeneron Pharmaceuticals, Inc. | DUPIXENT | dupilumab | Injection | 761055 | 10/20/2021 | ⤷ Try a Trial | 2034-09-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |